CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Handa Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Handa Pharmaceuticals Inc
3F-1&3F-2, No.23, Nanke 3rd Road
Nanbu Kexue Gongye Yuan District
Phone: +886 65057508p:+886 65057508 TAINAN, 741  Taiwan Ticker: 66206620
Business Summary
Handa Pharmaceuticals Inc is a Taiwan-based pharmaceutical company focused on the development of niche drug. The Company integrates its own pharmaceutical development platform with patent analysis, medicine and pharmaceuticals regulatory, and market planning to focus on the development of high barrier and patentable niche products, including 505(b)2 new drug development and high barrier/patentable generics development. Its products include marketed products, such as Quetiapine XR Tablets for treatment of sleep disorder diseases, Lamotrigine XR Tablets for treatment of anti-epileptic diseases and Dexlansoprazole DR Capsules for treatment of erosive reflux esophagitis and non-erosive gastroesophageal reflux diseases. The Company's products are mainly sold to the United States, Canada and India.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board FangyuLiu 12/12/2023 8/1/2016
Chief Technology Officer GuojunSong 8/22/2019 8/22/2019
General Manager, Director JunliangChen 6/28/2019 1/24/2019
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 13 (As of 12/31/2015)
Outstanding Shares: 141,202,000 (As of 10/7/2024)
Shareholders: 7,104
Stock Exchange: TPO
Fax Number: +886 65057502


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024